Visacor

البلد: نيوزيلاندا

اللغة: الإنجليزية

المصدر: Medsafe (Medicines Safety Authority)

العنصر النشط:

Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin;  ;  ;  

متاح من:

AstraZeneca Limited

INN (الاسم الدولي):

Rosuvastatin calcium 5.2 mg (= 5 mg rosuvastatin)

جرعة:

5 mg

الشكل الصيدلاني:

Film coated tablet

تركيب:

Active: Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin       Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Yellow Iron oxide yellow as Opadry Yellow Lactose monohydrate as Opadry Yellow   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Yellow Triacetin as Opadry Yellow

الوحدات في الحزمة:

Blister pack, Al/Al foil, 7 tablets

الفئة:

Prescription

نوع الوصفة الطبية :

Prescription

المصنعة من قبل:

Lonza AG

الخصائص العلاجية:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

ملخص المنتج:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 7 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

تاريخ الترخيص:

2009-07-31